Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma. 31723000 2020
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. 31040671 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. 30680510 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma. 30414187 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1. 30736462 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE Interestingly, however, BIG1 and BIG2 knockdown significantly decreased the levels of VEGF mRNA and protein in glioblastoma U251 cells and HUVECs. 31199673 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE In conclusion, the results suggest that the recurrence of GBM is associated with high gene expression levels VEGFA and CXCL8, and the development of the central nervous system. 31788092 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Using three glioblastoma cell-lines (U87, U251, and SNB19), the adaptation of glioblastoma cells in a 1% (hypoxia) and 20% (normoxia) oxygen microenvironment on proliferation, metabolism, migration, neurosphere formation, CD133 and VEGF expression was investigated. 31035344 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. 30718358 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Therefore, while under normoxic conditions, EGF stimulates the activation of both the PI3K and the MAPK pathways and the induction of VEGF, in glioblastoma cells, hypoxic conditions lead to the suppression of the PI3K/RhoA/C pathway and an exclusive switch to the MAPK pathway. 31698752 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Given that VEGF is a modulator of the innate immune response we sought to analyze the dynamics of this response in a mouse model of GBM undergoing anti-VEGF therapy. 31660979 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE Proangiogenic cytokines such as VEGF and angiopoietin-2 (Ang-2) have high expression in glioblastoma in a cell-specific manner and not only drive tumor angiogenesis and vascular permeability but also negatively regulate T-lymphocyte and innate immune cell responses. 31597643 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Recently, we evaluated modular peptide carrier L1 bearing CXCR4 targeting ligand for its ability to condense siRNA and facilitate endosomal escape and VEGFA gene silencing in CXCR4-expressing endothelial and glioblastoma cells. 31098995 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME. 31713115 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE VEGF blockade is still widely used as salvage therapy for recurrent GBM, therefore these intriguing results have potential translational implications as they point to a potential new strategy to overcome VEGF blockade resistance; however, they also raise important questions for the clinical translation of this strategy, and its impact on antitumor responses, in particular immune responses.<i>See related article by Mastrella et al., p. 2298</i>. 31043429 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Moreover, stellettin B blocks the expression and secretion of a major proangiogenic factor, vascular endothelial growth factor (VEGF), in glioblastoma cells. 30769863 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 GeneticVariation disease BEFREE Genetic ablation of interleukin-1 ligands or receptor in mice bearing RCAS/tv-a-induced platelet-derived growth factor B-overexpressing glioblastoma results in reduced oedema and partial restoration of the integrity of the blood-brain barrier, respectively; similar to results obtained with vascular endothelial growth factor neutralization. 31665239 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy. 30368528 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE As a second line treatment of glioblastomas, the vascular endothelial growth factor (VEGF) antibody bevacizumab is administered in combination with the TOP1 inhibitor irinotecan and glioblastoma cell levels of TIMP-1 could therefore potentially influence the efficacy of such treatment. 28963609 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Downregulation of the miR-221/222 cluster diminished the invasion, migration, proliferation, and angiogenesis with reduced protein levels of matrix metalloproteinase-2 (MMP-2), MMP-9, and vascular endothelial growth factor in glioblastoma cells. 31106423 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 GeneticVariation disease BEFREE Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach. 31554364 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor. 29573206 2018
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE The expression of FAT1, EMT (Snail/LOX/Vimentin/N-cad), stemness (SOX2/OCT4/Nestin/REST) and hypoxia markers (HIF-1α/VEGF/PGK1/CA9) was upregulated in ≥39% of GBM tumors (n = 31) with significant positive correlation (p ≤ 0.05) of the expression of FAT1 with LOX/Vimentin/SOX2/HIF-1α/PGK1/VEGF/CA9. 28994107 2018
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 GeneticVariation disease BEFREE The VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblastoma (odds ratio = 155.66), confirmed after Bonferroni correction. 29584591 2018
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive response rates for recurrent GB and has been approved as second-line therapy. 29950856 2018